FDA proposes excluding Novo, Lilly weight loss drugs from bulk compounding list in win for the companies

[U.S. News]

If that proposal is finalized, the exclusion would likely limit the mass compounding of those medicines unless they appear on the FDA's ⁠drug shortage ⁠list.

Continue reading...